Centers | ||
test | UCSC Chemical Screening Center | Chulalongkorn University Drug Discovery and Drug Development Research Center (Chula4DR) |
sfgd |
We are a shared research facility dedicated to improving human health by finding therapeutic agents against a wide variety of diseases, dedicated to advancing scientific knowledge and technologies, and dedicated to education of the next generation of... |
Chulalongkorn
Drug Discovery and Drug Development Research Center (Chula4DR) was
established in 2017, with the aim to facilitate advancement of academic
drug discovery and drug development research by leveraging innovations
and sciences... Read more |
Partnerships |
Events |
Jobs |
Johns Hopkins BSi Licenses GCPII Assets from EisaiJohns Hopkins Brain Science Institute ("BSi") has taken a non-exclusive license from Eisai to develop new compounds related to Glutamate Carboxypeptidase II (GCP-II) technology. The new compounds developed under this license will be targeted... View all JDRF & Novo Nordisk to Collaborate on Type 1 DiabetesJDRF and Novo Nordisk have entered into collaboration to develop new immunotherapies to treat Type 1 diabetes. The new partnership will be based out of Novo's newly opened Type 1 Diabetes R&D Center in Seattle. JDRF and Novo Nordisk will be... View all Janssen Partners with Evotec-Harvard Diabetes Collaboration ProgramJanssen Pharmaceutical a division of Johnson & Johnson has entered into partnership with Harvard University - Evotec's Diabetes program called CureBeta. Janssen will paying $300million in milestone payments per product in addition to $8million in... View all |
No EVENTS for listing |
No Job Posts |


